Daily Newsletter

01 September 2023

Share with colleague
Subscribe

Daily Newsletter

01 September 2023

Share with colleague
Subscribe

Spotlight

23andMe expands cancer at-home genetic report

23andMe received FDA clearance to report 41 additional genetic variants of BRCA1 and BRCA2 genes.

Latest news

Beta Bionics collects $100m in Series D funding

Beta Bionics plans to expand its marketing operations and advance its diabetes technology after the close of Series D funding round.

01 September 2023

Rapid Medical receives Chinese approval for revascularisation device

The TIGERTRIEVER device facilitates precise control during mechanical thrombectomy.

01 September 2023

Aspira and The University of Oxford sign serums sample agreement

Aspira expects to use the samples for supporting the launch of its first-generation blood test, EndoCheck.

01 September 2023

UC Santa Cruz develops new liquid biopsy platform for cancer diagnosis

The lab developed an advanced platform called COMPLETE-seq for cell-free RNA sequencing and analysis.

01 September 2023

CytoSorbents receives expanded registration from ANVISA for CytoSorb

CytoSorb is now available for purchase in Brazil through FMC in the Critical Care segment.

01 September 2023

FDA clears Daye’s gamma-irradiated Nude tampon

Daye is disrupting the women's health space, its organic tampon is passed through gamma rays which reduce the risk of vaginal infections.

01 September 2023

Epineuron enrols first patient in nerve regeneration study

The therapy, applied during or shortly after surgery, works by upregulating regeneration-associated genes.

01 September 2023

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.